Naif I AlJohani

6PUBLICATIONS
2CO-AUTHORS
Gene and molecular therapyRegenerative medicine (incl. stem cells)Reaction kinetics and dynamicsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 29, 2026
Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor.

|Jul 05, 2026
Immortal time bias limits the conclusion that post-transplant hypomethylating agent maintenance improves outcomes in myelodysplastic syndromes.

|Jul 01, 2026
Excellent clinical and patient-reported outcomes following matched sibling donor BMT for sickle cell disease.

|Jun 03, 2026
Defining durability in SCD gene therapy.

|Jul 18, 2022
What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti-thymocyte globulin?

Naif I AlJohani, Amir Ahmed Toor

|Nov 29, 2021
Effect of non-pharmacological interventions on the COVID-19 epidemic in Saudi Arabia.

Naif I AlJohani, Kipkoech Mutai

Pageof 1

Frequent Collaborators

1 joint publications

Amir Ahmed Toor

1 joint publications

Raniah Jaha